Updated

Novo Nordisk raised its full-year outlook on Wednesday after quarterly sales of its Wegovy pill ran ahead of analyst expectations. CNBC reported that the company posted its quarterly results early in the day, ahead of consensus forecasts. The Wegovy pill's sales were the main driver of the stronger results, according to the report. The company's upgraded guidance reflects the stronger demand for the oral weight-loss product.